Outlook Therapeutics Launches Best-Efforts Offering of Stock and Warrants Via H.C. Wainwright
Outlook Therapeutics has launched a best-efforts public offering of common stock and pre-funded warrants with accompanying warrants, engaging H.C. Wainwright as exclusive placement agent. Net proceeds will finance working capital and general corporate purposes under its April 5, 2024 shelf registration.
1. Proposed Public Offering Details
Outlook Therapeutics commenced a best-efforts public offering of common stock or pre-funded warrants, each paired with warrants exercisable for common shares. H.C. Wainwright has been engaged as exclusive placement agent for the transaction, which remains subject to market conditions and customary closing requirements.
2. Use of Proceeds
The company intends to allocate net proceeds primarily to working capital and general corporate purposes, aiming to sustain ongoing operations, support development activities for ONS-5010/LYTENAVA™, and manage near-term expenses.
3. Shelf Registration and Timing
The offering is conducted under a shelf registration on Form S-3 that became effective on April 5, 2024. Final size, pricing and timing of the offering will depend on market demand and regulatory approvals.
4. Pipeline and Commercial Launch
Outlook Therapeutics recently launched LYTENAVA™ in Germany, Austria and the UK for wet AMD and continues investigational U.S. studies of ONS-5010 as a potential first approved ophthalmic bevacizumab formulation for retina diseases.